BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis 2008;27:891-9. [PMID: 18629558 DOI: 10.1007/s10096-008-0520-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Straňák Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, Unnebrink K, van Wyk J, Wegzyn C, Notario G, Kalus S, Campbell FJ. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI). PLoS One 2016;11:e0157446. [PMID: 27310438 DOI: 10.1371/journal.pone.0157446] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
2 Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Nair S, Jones MA, Thorning S, Conly JM. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2011;:CD006207. [PMID: 21735402 DOI: 10.1002/14651858.CD006207.pub4] [Cited by in Crossref: 130] [Cited by in F6Publishing: 154] [Article Influence: 11.8] [Reference Citation Analysis]
3 Figueras Aloy J, Carbonell Estrany X. Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 32 1 a 35 0 semanas de gestación. Anales de Pediatría 2010;73:98.e1-4. [DOI: 10.1016/j.anpedi.2010.05.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
4 Figueras-Aloy J, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; Grupo IRIS. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain]. An Pediatr (Barc) 2009;71:47-53. [PMID: 19524492 DOI: 10.1016/j.anpedi.2009.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
5 Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Nair S, Foxlee R, Rivetti A. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2010;:CD006207. [PMID: 20091588 DOI: 10.1002/14651858.CD006207.pub3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
6 Sow FB, Gallup JM, Krishnan S, Patera AC, Suzich J, Ackermann MR. Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs. Respir Res 2011;12:106. [PMID: 21827668 DOI: 10.1186/1465-9921-12-106] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
7 Luo G, Nkoy FL, Gesteland PH, Glasgow TS, Stone BL. A systematic review of predictive modeling for bronchiolitis. Int J Med Inform. 2014;83:691-714. [PMID: 25106933 DOI: 10.1016/j.ijmedinf.2014.07.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
8 Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ, Alfaro N, Lázaro P. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis 2014;14:544. [PMID: 25358423 DOI: 10.1186/s12879-014-0544-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
9 Kool-houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands. Acta Paediatr 2015;104:927-32. [DOI: 10.1111/apa.13081] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Jefferies K, Drysdale SB, Robinson H, Clutterbuck EA, Blackwell L, McGinley J, Lin GL, Galal U, Nair H, Aerssens J, Öner D, Langedijk A, Bont L, Wildenbeest JG, Martinon-Torres F, Rodríguez-Tenreiro Sánchez C, Nadel S, Openshaw P, Thwaites R, Widjojoatmodjo M, Zhang L, Nguyen TL, Giaquinto C, Giordano G, Baraldi E, Pollard AJ; RESCEU Investigators. Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). J Infect Dis 2020;222:S658-65. [PMID: 32794560 DOI: 10.1093/infdis/jiaa239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bont L, Blanken M. Viral respiratory burden in moderate-to-late preterm infants. Early Hum Dev 2013;89 Suppl 1:S37-9. [PMID: 23809347 DOI: 10.1016/S0378-3782(13)70012-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Pike KC, Lucas JS. Respiratory consequences of late preterm birth. Paediatr Respir Rev 2015;16:182-8. [PMID: 25554628 DOI: 10.1016/j.prrv.2014.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
13 Cho HJ, Shim SY, Son DW, Sun YH, Tchah H, Jeon IS. Respiratory viruses in neonates hospitalized with acute lower respiratory tract infections. Pediatr Int 2013;55:49-53. [PMID: 22978535 DOI: 10.1111/j.1442-200X.2012.03727.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
14 Kusuda S, Takahashi N, Saitoh T, Terai M, Kaneda H, Kato Y, Ohashi A, Watabe S, Joh-o K, Hirai K. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan. Pediatr Int 2011;53:368-73. [PMID: 20854284 DOI: 10.1111/j.1442-200X.2010.03249.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
15 Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol 2013;2013:359683. [PMID: 23840240 DOI: 10.1155/2013/359683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Jones MA, Thorning S, Beller EM, Clark J, Hoffmann TC, Glasziou PP, Conly JM. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020;11:CD006207. [PMID: 33215698 DOI: 10.1002/14651858.cd006207.pub5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
17 Brown PM, Schneeberger DL, Piedimonte G. Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev 2015;16:232-40. [PMID: 26074450 DOI: 10.1016/j.prrv.2015.05.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]